17 research outputs found
Primary open angle glaucoma due to T377M MYOC: Population mapping of a Greek founder mutation in Northwestern Greece
BACKGROUND: Mutations in the MYOC gene have been shown to explain 5% of unrelated primary open angle glaucoma (POAG) in different populations. In particular, the T377M MYOC mutation has arisen at least three separate times in history, in Great Britain, India, and Greece. The purpose of this study is to investigate the distribution of the mutation among different population groups in the northwestern region of Greece. MATERIALS AND METHODS: We explored the distribution of the "Greek" T377M founder mutation in the Epirus region in Northwestern Greece, which could be its origin. Genotyping was performed in POAG cases and controls by PCR amplification of the MYOC gene, followed by digestion with restriction enzyme. Statistical analyses were performed by an exact test, the Kaplan-Meier method and the t-test. RESULTS: In the isolated Chrysovitsa village in the Pindus Mountains, a large POAG family demonstrated the T377M mutation in 20 of 66 family members while no controls from the Epirus region (n = 124) carried this mutation (P < 0.001). Among other POAG cases from Epirus, 2 out of 14 familial cases and 1 out of 80 sporadic cases showed the mutation (P = 0.057). The probability of POAG diagnosis with advancing age among mutation carriers was 23% at age 40, and reached 100% at age 75. POAG patients with the T377M mutation were diagnosed at a mean age of 51 years (SD +/- 13.9), which is younger than the sporadic or familial POAG cases: 63.1 (SD +/- 11) and 66.8 (SD +/- 9.8) years, respectively. CONCLUSIONS: The T377M mutation was found in high proportion in members of the Chrysovitsa family (30.3%), in lower proportion in familial POAG cases (14.2%) and seems rare in sporadic POAG cases (1.2%), while no controls (0%) from the Epirus region carried the mutation. Historical and geographical data may explain the distribution of this mutation within Greece and worldwide
De Novo Transcriptome of Safflower and the Identification of Putative Genes for Oleosin and the Biosynthesis of Flavonoids
Safflower (Carthamus tinctorius L.) is one of the most extensively used oil crops in the world. However, little is known about how its compounds are synthesized at the genetic level. In this study, Solexa-based deep sequencing on seed, leaf and petal of safflower produced a de novo transcriptome consisting of 153,769 unigenes. We annotated 82,916 of the unigenes with gene annotation and assigned functional terms and specific pathways to a subset of them. Metabolic pathway analysis revealed that 23 unigenes were predicted to be responsible for the biosynthesis of flavonoids and 8 were characterized as seed-specific oleosins. In addition, a large number of differentially expressed unigenes, for example, those annotated as participating in anthocyanin and chalcone synthesis, were predicted to be involved in flavonoid biosynthesis pathways. In conclusion, the de novo transcriptome investigation of the unique transcripts provided candidate gene resources for studying oleosin-coding genes and for investigating genes related to flavonoid biosynthesis and metabolism in safflower
COST-EFFECTIVENESS OF PONATINIB IN THE TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIA CHROMOSOME POSITIVE (PH plus ALL), SUITABLE FOR ALLOGENEIC STEM CELL TRANSPLANT, IN GREECE
HYPERINSULINEMIC HYPOGLYCEMIA (NESIDIOBLASTOSIS) - OUTCOME OF 7 CASES TREATED WITH LOW LEUCINE DIET AND DIAZOXIDE
Unusual absence of neurologic symptoms in a six-year old girl with ataxia-telangiectasia
Ataxia-telangiectasia (A-T) is a rare multisystem, neurodegenerative genetic disorder. We present a case of a 6-year-old girl who had a history of frequent respiratory infections and also had ocular and immunological features of this syndrome. The absence of neurological symptoms, which is very unusual for a patient of this age, raised many difficulties in the diagnosis of the disease. It is concluded that a normal neurological assessment must not exclude the diagnosis of A-T and delay the proper interventional measures
Campylobacter jejuni O:19 serotype-associated Guillain–Barré syndrome in a child: the first case reported from Greece
We present a case of Guillain–Barré syndrome (GBS) following Campylobacter jejuni HS serotype O:19 infection in a child. Antibodies against C. jejuni and autoantibodies to the peripheral nerve gangliosides GM1 were positive, a pattern correlating well with the existence of an inflammatory neuropathy like GBS. The patient shared the HLA-B35 and HLA-DR8 antigens, which have been found to be increased in GBS patients with previous C. jejuni infection. As this is the first diagnosed C. jejuni-associated GBS case reported from Greece, further clinical and epidemiologic investigations are warranted
Campylobacter jejuni O : 19 serotype-associated Guillain-Barre syndrome in a child: the first case reported from Greece
We present a case of Guillain-Barre syndrome (GBS) following
Campylobacter jejuni HS serotype 0:19 infection in a child. Antibodies
against C. jejuni and autoantibodies to the peripheral nerve
gangliosides GM1 were positive, a pattern correlating well with the
existence of an inflammatory neuropathy like GBS. The patient shared the
HLA-B35 and HLA-DR8 antigens, which have been found to be increased in
GBS patients with previous C. jejuni infection. As this is the first
diagnosed C. jejuni-associated GBS case reported from Greece, further
clinical and epidemiologic investigations are warranted
Calcium and vitamin D metabolism in hypocalcemic vitamin D-resistant rickets carriers
Background/Aims: Hypocalcemic vitamin D-resistant rickets (HVDRR) is a
rare monogenic autosomal recessive disorder associated with mutations in
the gene of the vitamin D receptor (VDR), the mediator of 1,25(OH)(2)D-3
action. Although many investigations have discussed the clinical
manifestations and molecular etiology of this disease, only a few have
investigated the biochemical and hormonal status of heterozygous HVDRR.
The aim of the current work was to investigate the profile of selected
biochemical and hormonal parameters related to the vitamin D endocrine
system in a large number of HVDRR heterozygotes. Methods: 67 relatives
of 2 HVDRR patients, all members of an extended Greek kindred of five
generations with a common ancestor, were included in the study. Direct
sequencing was used to identify VDR gene mutations. Serum Ca, P,
25(OH)D, iPTH, and 1,25(OH)(2)D levels were determined in all members of
the kindred. Results: DNA analysis of the participants led to the design
of two study groups: the HVDRR carriers (24) and the control subjects
(43). Our results showed elevated circulating serum levels of
1,25(OH)(2)D-3 and lower levels of PTH than their age- and sex-matched
controls. No hypocalcemia or hypophosphatemia were detected in HVDRR
carriers. Conclusions: Our findings suggest that HVDRR carriers may have
compensatory elevated serum levels of 1,25(OH)(2)D-3 through which they
restrain PTH secretion. The study of HVDRR carriers could be a useful
tool for the investigation of the vitamin D endocrine system. Copyright
(c) 2006 S. Karger AG, Basel
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty-seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the patients were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2-16), and the median time to best response was the fourth cycle. Fifty-seven patients achieved an objective response: twenty-two (23%), a complete response (CR), and 35 patients (37%), a partial, for an overall response rate of 60%. Twelve patients (13%) had stable disease, and the remaining twenty-six (27%) had progressive disease as their best response. At a median follow-up of 11.5 months, median progression-free survival and overall survival were 8 and 26.5 months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV (P =.005). Bulky disease (P =.01) and response to BV (P <.001) were significant for progression-free survival, while refractoriness to most recent treatment (P =.04), bulky disease (P =.005), and B-symptoms (P =.001) were unfavorable factors for overall survival. Among the 22 CRs, 5 remain in CR with no further treatment after BV at a median follow-up of 13 months. In conclusion, our data indicate that BV is an effective treatment for R/R HL patients even outside clinical trials. Whether BV can cure a fraction of patients remains to be seen. © 2017 The Authors Hematological Oncology Published by John Wiley & Sons Lt